Comparing the effectiveness of the new 5th generation cephalosporin, ceftobiprole, to daptomycin in treating S. aureus bacteremia
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on October 11th, 2023
|
As the rate of antimicrobial resistance increased, more cases of multidrug resistance bacteria occurred. Even last resort antibiotics such as methicillin had been nullified; thus, there is a need for new antimicrobial agents. Ceftobiprole is a 5th generation cephalosporin that can interfere with the bacteria wall-forming process. Thus, a study was conducted with the sponsorship of the US Department of Health and Human Services to assess its efficacy in treating bacteremia.
The phase 3 clinical trial included 387 patients who had been hospitalized with bacteremia due to S. aureus within the past 72 hours. The patients were randomly assigned to receive either ceftobiprole or daptomycin. 500 mg of ceftobiprole was administered intravenously every 6 hours for the first 8 days, and every 8 hours afterward. Daptomycin was administered intravenously at a dose of 6 mg per kilogram of body weight every 24 hours; the dose could be increased to 10 mg per kilogram of body weight every 24 hours. The study concluded that the rate of microbial eradication and treatment success was similar between the ceftobiprole and daptomycin group. The rate of mortality was also similar between the two groups. Moreover, Ceftobiprole was also very well tolerated, with gastrointestinal problems the most commonly reported adverse effect.
The phase 3 clinical trial included 387 patients who had been hospitalized with bacteremia due to S. aureus within the past 72 hours. The patients were randomly assigned to receive either ceftobiprole or daptomycin. 500 mg of ceftobiprole was administered intravenously every 6 hours for the first 8 days, and every 8 hours afterward. Daptomycin was administered intravenously at a dose of 6 mg per kilogram of body weight every 24 hours; the dose could be increased to 10 mg per kilogram of body weight every 24 hours. The study concluded that the rate of microbial eradication and treatment success was similar between the ceftobiprole and daptomycin group. The rate of mortality was also similar between the two groups. Moreover, Ceftobiprole was also very well tolerated, with gastrointestinal problems the most commonly reported adverse effect.